Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rhian Siân, Davies"'
Autor:
Rachel Butler, Rhian Siân Davies, Gwenllian Edwards, Christian Smith, Diane Parry, Jason F. Lester
Publikováno v:
Lung Cancer International
Objectives. There have been advances in the identification and understanding of molecular subsets of lung cancer, defined by specific oncogenic aberrations. A number of actionable genetic alterations have been identified, such as the epidermal growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::208cb26110b8b2d0b049fb0ec581d5ac
https://pubmed.ncbi.nlm.nih.gov/28367333
https://pubmed.ncbi.nlm.nih.gov/28367333
Publikováno v:
Anticancer research. 36(8)
In advanced non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) mutations L858R and exon 19 deletion (del19) predict response to EGFR tyrosine kinase inhibitors (TKIs). Trials have suggested a differential response to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::549e9ae92ac7181992b29c3628e1050a
https://pubmed.ncbi.nlm.nih.gov/27466542
https://pubmed.ncbi.nlm.nih.gov/27466542
Autor:
Jason F. Lester, Rhian Siân Davies, Jim Barber, M.R. Button, Jane Powell, Christian Smith, Jacob Tanguay, Teresa Perrett, Dennis Cochlin
Publikováno v:
Medical dosimetry : official journal of the American Association of Medical Dosimetrists. 41(4)
A study was performed to establish whether transrectal ultrasound (TRUS)-based postimplant dosimetry (PID) is both practically feasible and comparable to computed tomography (CT)-based PID, recommended in current published guidelines. In total, 22 pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c72c31d7bd30e25b479270f420064e
https://pubmed.ncbi.nlm.nih.gov/27623391
https://pubmed.ncbi.nlm.nih.gov/27623391
Autor:
Rhian Siân, Davies, Christian, Smith, Michael Robert, Button, Jacob, Tanguay, Jim, Barber, Nachiappan, Palaniappan, John, Staffurth, Jason Francis, Lester
Publikováno v:
Anticancer research. 35(10)
Several treatments have been shown to prolong survival in metastatic castrate-resistant prostate cancer (mCRPC); the optimum sequencing of these is not established. We investigated methods of identifying patients with mCRPC unlikely to respond to abi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::720f8ceeee368deab9dbe550e032746e
https://pubmed.ncbi.nlm.nih.gov/26408734
https://pubmed.ncbi.nlm.nih.gov/26408734